Table 1.
Patient characteristics
| Parameter | Mutation group, no. (%) |
P | ||
|---|---|---|---|---|
| Mutation (N = 86) | No mutation (N = 83) | |||
| Median age, y (range) | 52 (17-80) | 48 (21-94) | .311 | |
| Prior interferon-α | 57 (66) | 42 (51) | .060 | |
| Stage at imatinib therapy | CP | 68 (79) | 64 (77) | .530 |
| AP | 15 (17) | 13 (16) | ||
| BP | 3 (4) | 6 (7) | ||
| Best response to imatinib | CHR | 43 (50) | 35 (42) | .379 |
| MCyR | 33 (38) | 34 (41) | .881 | |
| CCyR | 22 (26) | 26 (31) | .562 | |
| Median duration of response to imatinib therapy, mo (range) | 25 (2-68) | 29 (3-69) | .20 | |
| Mutation at imatinib failure | Low IC50 | 42 (49) | ||
| Intermediate IC50 | 25 (29) | |||
| High IC50 | 9 (10) | |||
| Unknown IC50 | 10 (12) | NA | NA | |
| Stage at TKI switch | CP | 30 (35) | 29 (35) | .150 |
| AP | 41 (48) | 30 (36) | ||
| BP | 15 (17) | 24 (29) | ||
| Second TKI | Dasatinib | 41 (48) | 40 (48) | .928 |
| Nilotinib | 45 (52) | 43 (52) | ||
| Median follow-up from second TKI switch, mo (range) | 23 (3-38) | 22 (3-36) | .861 | |
NA indicates not applicable.